Prevention and Treatment of Cardiac Rhythm Disorders in Pregnant Women with Arterial Hypertension
Keywords:
cardiac rhythm disorders, pregnancy, beta-blocker, methyldopa, Holter monitoringAbstract
To prevent and assess cardiac rhythm disorders (CRDs) and conduction disorders in pregnant women with gestational and chronic arterial hypertension .
References
1.Conti, E., Cascio, N. D., Paluan, P., Racca, G., Longhitano, Y., Savioli, G., Tesauro, M., Leo, R., Racca, F., & Zanza, C. (2024). Pregnancy Arrhythmias: Management in the Emergency Department and Critical Care. Journal of clinical medicine, 13(4), 1095. https://doi.org/10.3390/jcm13041095
2.2025 ESC Guidelines for the management of cardiovascular disease and pregnancy: Developed by the task force on the management of cardiovascular disease and pregnancy of the European Society of Cardiology (ESC)
Endorsed by the European Society of Gynecology (ESG) https://doi.org/10.1093/eurheartj/ehaf193
3.Tamirisa, K. P., Elkayam, U., Briller, J. E., Mason, P. K., Pillarisetti, J., Merchant, F. M., Patel, H., Lakkireddy, D. R., Russo, A. M., Volgman, A. S., & Vaseghi, M. (2022). Arrhythmias in Pregnancy. JACC. Clinical electrophysiology, 8(1), 120–135. https://doi.org/10.1016/j.jacep.2021.10.004
4.Fischer AJ, Diller GP, Uebing A, Nürnberg JH, Hebe J. Antiarrhythmic drugs-safety and efficacy during pregnancy. Herzschrittmacherther Elektrophysiol. 2021 Jun;32(2):145-151. English. doi: 10.1007/s00399-021-00759-2. Epub 2021 Mar 29. PMID: 33779803. https://pubmed.ncbi.nlm.nih.gov/33779803
5.Joglar JA, Page RL. Treatment of cardiac arrhythmias during pregnancy: safety considerations. Drug Saf. 1999 Jan;20(1):85-94. doi: 10.2165/00002018-1999Mariani MV, Pierucci N, La Fazia VM, Cipollone P, Micillo M, D'Amato A, Fanisio F, Ammirati G, Salagundla N, Lavalle C, Perrone MA. Antiarrhythmic Drug Use in Pregnancy: Considerations and Safety Profiles. J Cardiovasc Dev Dis. 2024 Aug 7;11(8):243. doi: 10.3390/jcdd11080243. PMID: 39195151; PMCID: PMC11354975.20010-00008. PMID: 9935279. https://pubmed.ncbi.nlm.nih.gov/9935279
6.Hudson RE, Metz TD, Ward RM, McKnite AM, Enioutina EY, Sherwin CM, Watt KM, Job KM. Drug exposure during pregnancy: Current understanding and approaches to measure maternal-fetal drug exposure. Front Pharmacol. 2023 Mar 23;14:1111601. doi: 10.3389/fphar.2023.1111601. PMID: 37033628; PMCID: PMC10076747. https://pmc.ncbi.nlm.nih.gov/articles/PMC10076747
7.Mariani MV, Pierucci N, La Fazia VM, Cipollone P, Micillo M, D'Amato A, Fanisio F, Ammirati G, Salagundla N, Lavalle C, Perrone MA. Antiarrhythmic Drug Use in Pregnancy: Considerations and Safety Profiles. J Cardiovasc Dev Dis. 2024 Aug 7;11(8):243. doi: 10.3390/jcdd11080243. PMID: 39195151; PMCID: PMC11354975. https://pubmed.ncbi.nlm.nih.gov/39195151




United Kingdom
Germany
France
Uzbekistan
Türkiye
Kazakhstan
Kyrgyzstan
Turkmenistan
Azerbaijan
India
Republic of Korea
Japan
United States of America
Kosovo
Italy
Spain
Poland
Netherlands
Belgium
Sweden
Norway
Finland
Denmark
Switzerland
Austria
Czech Republic
Hungary
Romania
Bulgaria
Greece
Portugal